Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологія·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологія·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% шанс
Polymarket

$11,314 Обс.

13% шанс
Polymarket

$11,314 Обс.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains strictly limited to internal R&D testing of the SmartDepot ultrasonic spray-dried PLGA microsphere platform on select peptides, with any commercial license explicitly optional and non-binding. The 14-month term was extended to a maximum of 24 months ending October 7, 2026, yet no technology-transfer or commercialization deal has materialized despite shared preclinical data on candidates such as once-monthly semaglutide formulations. Lilly’s parallel long-acting partnerships, including with Camurus, further dilute urgency, while the 30-day termination clause and weeks remaining until resolution leave little room for a last-minute binding agreement. Trader capital therefore strongly favors “No” at 87.5% implied probability.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Обсяг
$11,314
Дата завершення
Oct 7, 2026
Ринок відкрито
May 5, 2026, 8:02 PM ET

Вирішувач

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains strictly limited to internal R&D testing of the SmartDepot ultrasonic spray-dried PLGA microsphere platform on select peptides, with any commercial license explicitly optional and non-binding. The 14-month term was extended to a maximum of 24 months ending October 7, 2026, yet no technology-transfer or commercialization deal has materialized despite shared preclinical data on candidates such as once-monthly semaglutide formulations. Lilly’s parallel long-acting partnerships, including with Camurus, further dilute urgency, while the 30-day termination clause and weeks remaining until resolution leave little room for a last-minute binding agreement. Trader capital therefore strongly favors “No” at 87.5% implied probability.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Обсяг
$11,314
Дата завершення
Oct 7, 2026
Ринок відкрито
May 5, 2026, 8:02 PM ET

Вирішувач

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Пов'язане

icon for Skin cancer vaccine BLA submitted by June 30, 2027?

Skin cancer vaccine BLA submitted by June 30, 2027?

88%
icon for FDA approves Retatrutide this year?

FDA approves Retatrutide this year?

3%
icon for Skin cancer vaccine FDA approved by December 31, 2027?

Skin cancer vaccine FDA approved by December 31, 2027?

68%

Обережно з зовнішніми посиланнями.

Часті запитання

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — це ринок прогнозів на Polymarket, де трейдери купують і продають акції «Так» або «Ні» залежно від того, чи вірять вони, що ця подія станеться. Поточна краудсорсингова ймовірність — 13% для «Yes». Наприклад, якщо «Так» коштує 13¢, ринок колективно оцінює шанс цієї події в 13%. Ці шанси безперервно змінюються, коли трейдери реагують на нові події. Акції правильного результату погашаються по $1 кожна при вирішенні ринку.

Станом на сьогодні, «Eli Lilly licenses Peptron’s SmartDepot by October 7?» згенерував $11.3K загального обсягу торгів з моменту запуску ринку May 5, 2026. Цей рівень торгової активності відображає сильну залученість спільноти Polymarket та забезпечує, що поточні шанси базуються на глибокому пулі учасників ринку. Ви можете відстежувати рухи цін наживо та торгувати будь-яким результатом прямо на цій сторінці.

Щоб торгувати на «Eli Lilly licenses Peptron’s SmartDepot by October 7?», просто оберіть, чи вірите ви, що відповідь — «Так» або «Ні». Кожна сторона має поточну ціну, що відображає ймовірність ринку. Введіть суму та натисніть «Торгувати». Якщо ви купили акції «Так» і результат — «Так», кожна акція виплачує $1. Якщо «Ні» — ваші акції «Так» коштують $0. Ви також можете продати акції в будь-який час до вирішення.

Поточна ймовірність для «Eli Lilly licenses Peptron’s SmartDepot by October 7?» — 13% для «Yes». Це означає, що спільнота Polymarket вважає, що є 13% шанс, що ця подія станеться. Ці шанси оновлюються в реальному часі.

Правила вирішення для «Eli Lilly licenses Peptron’s SmartDepot by October 7?» точно визначають, що має статися для оголошення переможця — включаючи офіційні джерела даних. Ви можете переглянути повні критерії вирішення в розділі «Правила» на цій сторінці. Рекомендуємо уважно прочитати правила перед торгівлею.